Publications by authors named "C Ricordel"
Article Synopsis
- The study investigates the effectiveness of combined treatment with anti-PD-1 (nivolumab) and anti-CTLA-4 (ipilimumab) antibodies compared to standard platinum-based chemotherapy in older patients with advanced non-small-cell lung cancer (NSCLC).
- It focuses specifically on patients aged 70 years or older or those with an ECOG performance status of 2, as there is limited data on this demographic.
- The trial is a phase 3 randomized controlled study conducted across 30 sites in France, aiming to evaluate overall survival, progression-free survival, and safety of the treatments in the intended patient population.
Background: Capmatinib is a selective MET inhibitor with demonstrated efficacy in a phase II study of non-small cell lung cancer (NSCLC) patients harboring METex14 mutations. However, the real-world outcomes of capmatinib are largely unknown. From June 2019, the French Early Access Program (EAP) provided capmatinib to METex14 NSCLC patients who were ineligible for or for whom first-line standard therapies had failed.
View Article and Find Full Text PDFArticle Synopsis
- Pembrolizumab and nivolumab, two immunotherapy drugs, are used to treat advanced non-small cell lung cancer (NSCLC), and a recent study (IDEE) aimed to assess their safety and effectiveness in real-world conditions.
- The study included 117 patients, revealing a median age of 67 years, a 79% survival rate at 12 months, and a median time to treatment failure of 9.2 months, with 28% of failures due to toxicity.
- Overall, the findings suggest that the double-dose regimen is feasible, with no major safety or efficacy concerns identified from the real-life data.
Background: Post-intensive care syndrome could be responsible for inability to receive proper cancer treatment after ICU stay in patients with solid tumors (ST). Our purpose was to determine the factors associated with cancer treatment resumption and the impact of cancer treatment on the outcome of patients with ST after ICU stay.
Methods: We conducted a retrospective study including all patients with ST admitted to the ICU between 2014 and 2019 in a French University-affiliated Hospital.
Background: Management of stage-III-N2 non-small-cell lung cancer (NSCLC) based on a multimodal strategy (surgery or radiotherapycombined with systemic drugs) remains controversial. Patients are treated with a curative intent, and available data suggestprolonged survival after complete resection. However, no consensual definition of "tumor resectability" exists.
View Article and Find Full Text PDF